- Trial phase
- Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- Time to market
- Unknown, likely several years. Phase 3 (IPAX BrIGHT) began dosing in April 2026; no primary-completion or readout date has been disclosed, so approval (if trials succeed) is not expected before ~2030.
- Why 3/10
- No hard, dated binary catalyst for TLX101-Tx in the next ~12 months: the pivotal Phase 3 IPAX BrIGHT trial only dosed its first patient in April 2026 (readout years away), and the Phase 1 IPAX-2 safety readout (enrollment complete, no dose-limiting toxicities) is already out, so the program is a mid-stage asset with no pending regulatory decision at a diversified commercial-stage company, scoring a 3.
TLX101-Tx itself has no near-term stock catalyst, the Phase 3 IPAX BrIGHT trial (recurrent glioblastoma) just began enrolling, so the next meaningful events are enrollment/timeline updates, likely at Telix's R&D Day on September 22, 2026. Investors holding TLX should treat TLX101-Tx as a long-dated pipeline option; near-term share-price drivers are the commercial business (H1 2026 revenue $477M) and the September 11, 2026 PDUFA for the separate diagnostic TLX101-Px (Pixclara), not this therapy.
Price Chart
Executive Summary
TLX101-Tx (131I-iodofalan) is Telix Pharmaceuticals' investigational radiopharmaceutical therapy for glioblastoma (GBM), the most aggressive form of brain cancer. It is an early-to-mid-stage program: a Phase 1 trial (IPAX-2) finished enrollment in May 2026 with a clean safety profile (no dose-limiting toxicities at the maximum dose), and the pivotal Phase 3 trial (IPAX BrIGHT) in recurrent GBM dosed its first patient in April 2026, making it, per Telix, the first radiopharmaceutical therapy to reach Phase 3 for GBM. There is no near-term approval or readout catalyst for this specific drug; it sits inside a diversified, profitable, commercial-stage radiopharma company (TLX, ~$12.12; analyst mean price target ~$21.29) whose near-term share-price drivers are commercial results and a September 2026 PDUFA for a separate diagnostic (TLX101-Px/Pixclara).
How It Works
TLX101-Tx is a targeted radiation therapy for brain cancer: a radioactive iodine atom (iodine-131, which emits cell-killing beta radiation) attached to an amino-acid-like molecule (iodofalan). Glioblastoma cells take up this amino-acid mimic through the same transport pathways they use for nutrients, so the radiation is concentrated inside tumor cells rather than delivered as whole-body or whole-brain radiation, an approach called theranostics, because the same biology used to image the tumor (Telix's FET PET tracer) is used to target the therapy.
Trial Status
Phase 1 IPAX-2 trial in newly diagnosed glioblastoma completed patient enrollment in May 2026 with no dose-limiting toxicities observed at any dose level, including the maximum 2 x 5 GBq (10 GBq total). The pivotal Phase 3 IPAX BrIGHT trial in recurrent glioblastoma, described by Telix as the first radiopharmaceutical therapy to enter Phase 3 for GBM, dosed its first patient in April 2026. No efficacy results have been reported for either trial.
The Two-Sided Case
Upcoming Catalysts
- Telix R&D Day in New York, September 22, 2026, likely venue for IPAX BrIGHT enrollment/timeline guidance and any early TLX101-Tx data
- IPAX BrIGHT (Phase 3, recurrent GBM) enrollment progress and any interim updates
- Company-level, not this drug: FDA PDUFA date of September 11, 2026 for the separate diagnostic TLX101-Px (Pixclara); H1 2026 results already released August 20, 2026
- Any announcement of IPAX-1/IPAX-2 efficacy or translational data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Telix Pharmaceuticals Limited PRESS-RELEASE TLX ·Originating report